Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Umbilical Cord Blood Transplant for B-Cell Lymphoid Malignancies
NCT00387959Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2006
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in B cell lymphoma and chronic lymphocytic leukemia (CLL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Overall Survival at 1 Year and Event-Free Survival at 1 Year. Started Jul 2006; status: completed.
02
Drugs
rituximab
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00387959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387959.